← Back to Clinical Trials
Recruiting NCT00301119

NCT00301119 Lung Cancer Biomarkers and Screening

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT00301119
Status Recruiting
Phase
Sponsor NYU Langone Health
Condition Lung Cancer
Study Type OBSERVATIONAL
Enrollment 3,606 participants
Start Date 2000-05
Primary Completion 2030-05

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,606 participants in total. It began in 2000-05 with a primary completion date of 2030-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

RATIONALE: Screening tests that use biomarkers may help doctors find tumor cells early and plan effective treatment for lung cancer. PURPOSE: This clinical trial is studying biomarkers in screening participants for lung cancer.

Eligibility Criteria

DISEASE CHARACTERISTICS: * Screening Cohort * At high- or low-risk for lung cancer * Smoking history ≥ 20 pack years\* * With or without workplace exposure to asbestos * NOTE: \* Participants with \< 20 pack years of smoking are eligible if 50 years of age or older * Rule-Out Lung cancer group * Referred for evaluation of suspicious nodules with 1 of the following diagnoses: * Lung cancer * Nonmalignant nodules (control group) PATIENT CHARACTERISTICS: * Not pregnant * No prior malignancy except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY: * Not specified

Contact & Investigator

Central Contact

James J. Tsay, MD, MSc

✉ Jun-Chieh.Tsay@nyulangone.org

📞 212-598-6351

Principal Investigator

James J. Tsay, MD, MSc

PRINCIPAL INVESTIGATOR

NYU Langone Health

Frequently Asked Questions

Who can join the NCT00301119 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT00301119 currently recruiting?

Yes, NCT00301119 is actively recruiting participants. Contact the research team at Jun-Chieh.Tsay@nyulangone.org for enrollment information.

Where is the NCT00301119 trial being conducted?

This trial is being conducted at New York, United States.

Who is sponsoring the NCT00301119 clinical trial?

NCT00301119 is sponsored by NYU Langone Health. The principal investigator is James J. Tsay, MD, MSc at NYU Langone Health. The trial plans to enroll 3,606 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology